Carpal Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.70 M
- Revenue Growth 0.56%
- Profit Growth 7.00%
- Ebitda 7.64%
- Net Worth 23.52%
- Total Assets -1.90%
About Carpal Remedies
Carpal Remedies Private Limited (CRPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 November 2016 (Eight years and two months 30 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.70 M.
Milind Thakare, Mangesh Ghormare, and Nikesh Tol serve as directors at the Company.
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24304MH2016PTC287337
- Company No.
287337
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Nov 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Carpal Remedies?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Milind Thakare  | Director | 01-Nov-2016 | Current |
| Mangesh Ghormare | Director | 01-Nov-2016 | Current |
| Nikesh Tol | Director | 01-Nov-2016 | Current |
Financial Performance of Carpal Remedies.
Carpal Remedies Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.56% increase. The company also saw a slight improvement in profitability, with a 7% increase in profit. The company's net worth Soared by an impressive increase of 23.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Carpal Remedies?
In 2023, Carpal Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.70 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jan 2020 | Others | ₹0.70 M | Open |
How Many Employees Work at Carpal Remedies?
Unlock and access historical data on people associated with Carpal Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Carpal Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Carpal Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.